Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 13, 2014 08:00 ET | Source: Alcobra Ltd.

Alcobra Strengthens Management Team With Addition of Industry Veteran David C. Baker as Chief Commercial Officer

Led Efforts to Build Shire's Pipeline of ADHD and CNS Products Launched Vyvanse®, the #1 ADHD Brand in the U.S. Brand management experience on five different billion dollar brands...
December 18, 2013 09:50 ET | Source: Alcobra Ltd.

FDA Grants Orphan Drug Status to Metadoxine in Fragile X Syndrome

TEL AVIV, Israel, Dec. 18, 2013 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD) (the "Company"), an emerging biopharmaceutical company primarily focused on the development and commercialization of its...
December 16, 2013 09:00 ET | Source: Alcobra Ltd.

Alcobra Ltd. Announces Highly Statistically Significant Positive Phase IIb Clinical Trial Results in Adults With Predominantly Inattentive Attention Deficit Hyperactivity Disorder

- Primary endpoint analysis of improvement over placebo highly statistically significant at p < 0.01 - MG01CI, a non-stimulant, is superior to placebo starting at first dosing - Trial shows...
December 02, 2013 09:19 ET | Source: Alcobra Ltd.

Alcobra to Present at the 25th Annual Piper Jaffray Healthcare Conference

TEL AVIV, Israel, Dec. 2, 2013 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD) (the "Company"), an emerging biopharmaceutical company primarily focused on the development and commercialization of its...
November 22, 2013 08:00 ET | Source: Alcobra Ltd.

Alcobra Ltd. Announces New Findings on Diminished Abuse Potential of Its Proprietary Drug Candidate, MG01CI

TEL AVIV, Israel, Nov. 22, 2013 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD) (the "Company"), an emerging biopharmaceutical company primarily focused on the development and commercialization of its...
November 07, 2013 06:30 ET | Source: Alcobra Ltd.

Alcobra Ltd. Reports Third Quarter 2013 Results

TEL AVIV, Israel, Nov. 7, 2013 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD) (the "Company"), an emerging biopharmaceutical company primarily focused on the development and commercialization of its...
November 05, 2013 08:53 ET | Source: Alcobra Ltd.

Alcobra Successfully Completes Enrollment in Comparative Phase II Study of Attention and Cognitive Function Benefits in Patients With PI-ADHD

--Last patient visit scheduled for November 26, 2013 --Data expected to be announced during the week of December 16, 2013 TEL AVIV, Israel, Nov. 5, 2013 (GLOBE NEWSWIRE) -- Alcobra Ltd....
October 31, 2013 16:05 ET | Source: Alcobra Ltd.

Alcobra Ltd. to Host a Third Quarter 2013 Conference Call on November 7th

TEL AVIV, Israel, Oct. 31, 2013 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging biopharmaceutical company primarily focused on the development and commercialization of its proprietary...
October 30, 2013 13:48 ET | Source: Alcobra Ltd.

Alcobra Ltd. Announces Closing of Approximately $38 Million Public Offering of Ordinary Shares

TEL AVIV, Israel, Oct. 30, 2013 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging biopharmaceutical company primarily focused on the development and commercialization of its proprietary...
October 29, 2013 08:00 ET | Source: Alcobra Ltd.

Alcobra Ltd. Announces Full Exercise of Over-Allotment Option by Underwriters

TEL AVIV, Israel, Oct. 29, 2013 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging biopharmaceutical company primarily focused on the development and commercialization of its proprietary...